TY - JOUR
T1 - Extracellular vesicles from osteosarcoma cell lines contain miRNAs associated with cell adhesion and apoptosis
AU - Jerez, Sofía
AU - Araya, Héctor
AU - Hevia, Daniel
AU - Irarrázaval, Carlos E.
AU - Thaler, Roman
AU - van Wijnen, Andre J.
AU - Galindo, Mario
N1 - Funding Information:
This study was supported by National Fund for Scientific and Technological Development (FONDECYT Chile), grant numbers 1130931 (to MG) and 1151157 (to CEI), Millennium Science Initiative from Ministry for the Economy, Development and Tourism, Chile , grant number P09/016-F (to MG), Chilean Economic Development Agency ( CORFO , Chile) grant number 14IDL2-30168 (to CEI). Additional support was provided by PhD fellowship of the National Commission for Scientific and Technological Research (CONICYT Chile) (to SJ and HA). This work was also supported by National Institutes of Health (NIH) grant R01 AR049069 (to AJvW).
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/8/20
Y1 - 2019/8/20
N2 - Osteosarcoma is the most common primary bone tumor during childhood and adolescence. Several reports have presented data on serum biomarkers for osteosarcoma, but few reports have analyzed circulating microRNAs (miRNAs). In this study, we used next generation miRNA sequencing to examine miRNAs isolated from microvesicle-depleted extracellular vesicles (EVs) derived from six different human osteosarcoma or osteoblastic cell lines with different degrees of metastatic potential (i.e., SAOS2, MG63, HOS, 143B, U2OS and hFOB1.19). EVs from each cell line contain on average ~300 miRNAs, and ~70 of these miRNAs are present at very high levels (i.e., >1000 reads per million). The most prominent miRNAs are miR-21-5p, miR-143-3p, miR-148a-3p and 181a-5p, which are enriched between 3 and 100 fold and relatively abundant in EVs derived from metastatic SAOS2 cells compared to non-metastatic MG63 cells. Gene ontology analysis of predicted targets reveals that miRNAs present in EVs may regulate the metastatic potential of osteosarcoma cell lines by potentially inhibiting a network of genes (e.g., MAPK1, NRAS, FRS2, PRCKE, BCL2 and QKI) involved in apoptosis and/or cell adhesion. Our data indicate that osteosarcoma cell lines may selectively package miRNAs as molecular cargo of EVs that could function as paracrine agents to modulate the tumor micro-environment.
AB - Osteosarcoma is the most common primary bone tumor during childhood and adolescence. Several reports have presented data on serum biomarkers for osteosarcoma, but few reports have analyzed circulating microRNAs (miRNAs). In this study, we used next generation miRNA sequencing to examine miRNAs isolated from microvesicle-depleted extracellular vesicles (EVs) derived from six different human osteosarcoma or osteoblastic cell lines with different degrees of metastatic potential (i.e., SAOS2, MG63, HOS, 143B, U2OS and hFOB1.19). EVs from each cell line contain on average ~300 miRNAs, and ~70 of these miRNAs are present at very high levels (i.e., >1000 reads per million). The most prominent miRNAs are miR-21-5p, miR-143-3p, miR-148a-3p and 181a-5p, which are enriched between 3 and 100 fold and relatively abundant in EVs derived from metastatic SAOS2 cells compared to non-metastatic MG63 cells. Gene ontology analysis of predicted targets reveals that miRNAs present in EVs may regulate the metastatic potential of osteosarcoma cell lines by potentially inhibiting a network of genes (e.g., MAPK1, NRAS, FRS2, PRCKE, BCL2 and QKI) involved in apoptosis and/or cell adhesion. Our data indicate that osteosarcoma cell lines may selectively package miRNAs as molecular cargo of EVs that could function as paracrine agents to modulate the tumor micro-environment.
KW - Cancer
KW - Cell aggressiveness
KW - Exosomes
KW - Metastasis
KW - MicroRNA
KW - Osteosarcoma
UR - http://www.scopus.com/inward/record.url?scp=85067172954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067172954&partnerID=8YFLogxK
U2 - 10.1016/j.gene.2019.06.005
DO - 10.1016/j.gene.2019.06.005
M3 - Article
AN - SCOPUS:85067172954
SN - 0378-1119
VL - 710
SP - 246
EP - 257
JO - Gene
JF - Gene
ER -